Pritchard W F, Carey R F
Office of Science and Technology, U.S. Food and Drug Administration (HFZ-132), Rockville, MD 20852, USA.
Radiology. 1997 Oct;205(1):27-36. doi: 10.1148/radiology.205.1.9314955.
The recent decision by the U.S. Food and Drug Administration (FDA) to approve one ultrasound imaging system for use in making breast biopsy decisions prompted considerable interest in the radiology community about the regulatory process and the associated implications for the practice of medicine. In this report, the concepts and statutory authority guiding the FDA in the regulation of medical devices are summarized and discussed, including the device classification scheme, premarket approval, premarket notification, and investigational device exemptions. Also, the critical concepts of safety and effectiveness for a given indication for use, the roles of advisory panels, and examples of imaging and interventional devices are described to shed light on the approval process.
美国食品药品监督管理局(FDA)最近做出决定,批准一款超声成像系统用于辅助乳腺活检决策,这引发了放射学界对监管程序以及医学实践相关影响的极大关注。在本报告中,将总结并讨论指导FDA对医疗器械进行监管的概念和法定权限,包括器械分类方案、上市前批准、上市前通知以及研究性器械豁免。此外,还将描述针对特定使用适应症的安全性和有效性的关键概念、咨询小组的作用以及成像和介入器械的示例,以阐明批准过程。